Table 1.
Main sample features (n = 1489).
| Center | |||
|---|---|---|---|
| No. 1 (n = 880) | No. 2 (n = 609) | ||
| Vaccine | Live attenuated virus | 836 (95.0) | 592 (97.2) |
| Recombinant vaccine | 44 (5.0) | 17 (2.8) | |
| Gender | Male | 448 (50.9) | 281 (46.1) |
| Female | 432 (49.1) | 328 (53.9) | |
| Age | 67 | 278 (31.6) | 303 (49.8) |
| 66 | 286 (32.5) | 278 (45.7) | |
| 65 | 299 (34.0) | 24 (3.9) | |
| Other | 17 (1.9) | 4 (0.7) | |
| Pathological Anamnesis | Neurological disorders | 18 (2.1) | 9 (1.5) |
| Primary immunodeficiency | 13 (1.5) | 12 (2.0) | |
| Allergies | 76 (8.7) | 86 (14.1) | |
| Vaccine allergies | 6 (0.7) | 3 (0.5) | |
| Iatrogenic immunosuppression | 32 (3.6) | 11 (1.8) | |
| History of Herpes Zoster | Personal | 114 (17.4) | 91 (17.0) |
| Relatives | 217 (33.3) | 201 (37.4) | |
| Vaccination Campaign-source of information | Text-message | 621 (95.1) | 456 (85.7) |
| General practitioner | 10 (1.5) | 6 (1.1) | |
| Family/friends | 14 (2.1) | 48 (9.0) | |
| Web | 1 (0.2) | 7 (1.3) | |
| News | 3 (0.5) | 4 (0.8) | |
| Other | 4 (0.6) | 11 (2.1) | |